Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...

"Johnson & Johnson and Mitsubishi Tanabe Pharma’s Stelara (ustekinumab) and Eli Lilly and Sumitomo Dainippon Pharma’s Trulicity (dulaglutide) are ranked ninth and tenth,” Sabaratnam says.

The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.

Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...

Am J Health Syst Pharm. 2007;64(12):1265-1273.